Name: CJC-1295 ( NO DAC )
SKU: 9968
Availability: InStock

CJC-1295 with DAC is a synthetic long-acting analogue of growth hormone-releasing hormone (GHRH) designed to produce sustained stimulation of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis.

The peptide contains a Drug Affinity Complex (DAC) modification that enables prolonged association with circulating albumin. This substantially extends its biological persistence compared with native GHRH and shorter-acting GHRH analogues.

Research has examined CJC-1295 with DAC in relation to:

endogenous growth hormone secretion;
circulating IGF-1;
pituitary GHRH receptor signalling;
GH pulse amplitude;
metabolic regulation;
body-composition biology;
tissue-repair signalling;
prolonged somatotropic-axis activation.

The Atlas Longevity CJC-1295 with DAC pen contains 5 mg in a 3 mL cartridge with 300 total units/clicks.

CJC-1295 with DAC remains an investigational research peptide. The supplied material describes early human pharmacokinetic research alongside animal and in-vitro evidence, but it is not presented as an approved medicine.

Clinical / Research Status

The supplied material describes CJC-1295 with DAC as having undergone limited early-phase human investigation, particularly in pharmacokinetic and GH/IGF-1 research.

Evidence Type	Status Based on Supplied Material
Human randomized clinical research	Not established by supplied status section
Human observational / early-phase research	Yes
Animal research	Yes
In-vitro research	Yes
Regulatory approval	No

The source’s evidence table marks human RCT evidence as absent while some later references are labelled as human RCTs. For Atlas content, the more cautious description is therefore limited human pharmacokinetic and endocrine research rather than a broad established clinical evidence base.

Evidence Type

The supplied material describes research involving:

healthy adult human pharmacokinetic studies;
repeated human exposure studies;
pituitary-cell research;
GHRH receptor assays;
aged-animal models;
growth-hormone-deficient animal models.

The strongest source-supported findings concern prolonged GH and IGF-1 elevation following CJC-1295 with DAC exposure.

Claims involving muscle gain, fat loss, sleep, skin rejuvenation, bone density, or anti-ageing should remain secondary and research-oriented.

Mechanism of Action

CJC-1295 with DAC acts as a GHRH receptor agonist.

It binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating endogenous growth hormone secretion.

The resulting increase in GH can subsequently increase production of:

IGF-1

primarily through hepatic GH signalling.

GHRH Receptor Activation

Activation of the GHRH receptor stimulates intracellular signalling associated with:

adenylate cyclase;
cAMP;
protein kinase A;
GH synthesis;
GH secretion.

Drug Affinity Complex (DAC)

The defining feature of CJC-1295 with DAC is its albumin-binding DAC modification.

The source describes this as allowing prolonged association with serum albumin, substantially slowing peptide clearance.

This is the basis for the source-reported half-life of approximately:

6–8 days

compared with the much shorter persistence of native GHRH.

Sustained GH / IGF-1 Signalling

Because the compound remains biologically available for longer, experimental exposure can produce more prolonged changes in:

mean GH concentration;
GH pulse amplitude;
IGF-1 levels.

The supplied material specifically describes sustained increases rather than complete replacement of physiological GH pulsatility.

CJC-1295 with DAC vs CJC-1295 No-DAC

The two compounds should not be treated as interchangeable.

CJC-1295 with DAC

Designed for long-duration systemic exposure through albumin binding.

Source-reported half-life:

approximately 6–8 days

CJC-1295 No-DAC

A much shorter-acting GHRH analogue without the albumin-binding DAC modification.

Its pharmacokinetic behaviour and research design are therefore substantially different.

Any click calculations, timing concepts, or research interpretation should be kept specific to the exact CJC-1295 variant being discussed.

Potential Benefits / Research Areas

Sustained Growth Hormone Research

The main research characteristic of CJC-1295 with DAC is its ability to produce prolonged stimulation of endogenous GH secretion.

Human research described by the source reports elevated mean GH concentrations for several days following exposure.

This makes CJC-1295 with DAC useful in models examining chronic rather than brief GHRH receptor stimulation.

IGF-1 Research

Increased GH signalling can raise circulating IGF-1.

The source reports prolonged IGF-1 elevations following CJC-1295 with DAC administration, extending beyond the initial GH response.

This is one of the most clearly described downstream endpoints in the supplied material.

GH Pulsatility Research

The source states that CJC-1295 with DAC can increase GH pulse amplitude while preserving endogenous pulsatile characteristics.

This makes the compound relevant to research into:

somatotropic-axis physiology;
GH pulse architecture;
long-duration GHRH stimulation.

Body-Composition Research

Because the GH/IGF-1 axis influences protein and lipid metabolism, CJC-1295 with DAC has been studied in experimental models involving:

lean tissue;
adipose tissue;
protein metabolism;
body composition.

Most claims involving significant muscle gain or fat loss remain more preclinical than established human outcomes.

Lipolysis Research

Growth hormone participates in adipose-tissue metabolism and lipolytic signalling.

The supplied source discusses experimental reductions in visceral and subcutaneous fat in selected models.

These findings should not be translated into guaranteed human fat-loss outcomes.

Tissue-Repair Research

The GH–IGF-1 axis participates in:

fibroblast signalling;
collagen synthesis;
satellite-cell biology;
connective-tissue turnover.

CJC-1295 with DAC is therefore discussed in experimental tissue-repair and recovery research.

This does not establish the compound as an approved treatment for injury or musculoskeletal repair.

Sleep and GH-Release Research

Growth hormone secretion is physiologically associated with sleep, particularly slow-wave sleep.

The supplied source discusses CJC-1295 with DAC in relation to sleep architecture and nocturnal GH signalling.

However, evidence for direct sleep improvement is weaker than the pharmacokinetic evidence for GH and IGF-1 elevation.

Bone and Skeletal Research

GH and IGF-1 influence bone remodelling.

Experimental research described by the source discusses:

osteoblast activity;
collagen type I;
mineralisation;
skeletal remodelling.

These findings remain research-oriented and should not be presented as proof of improved human bone density.

Skin and Collagen Research

The source also discusses experimental effects on dermal collagen and extracellular-matrix biology.

This provides a mechanistic basis for skin-related research but does not establish anti-ageing or cosmetic rejuvenation outcomes.

Metabolic Research

Sustained GH elevation can influence:

glucose metabolism;
insulin sensitivity;
lipid metabolism;
substrate utilisation.

These effects can be complex and may include reduced insulin sensitivity rather than uniformly beneficial metabolic changes.

Research Data

Study / Model	Reported Finding
Healthy adult human PK study	Mean plasma GH reportedly increased approximately 2–10 fold for several days, with IGF-1 elevated for longer
Repeated human exposure	Sustained IGF-1 elevation across repeated exposure periods
Human pharmacokinetic research	Source-reported effective half-life approximately 5.8–8.1 days
Rat pituitary-cell cultures	GHRH receptor activation with preserved pulsatile GH release
Aged rodent models	Increased GH pulse amplitude with body-composition changes
GH-deficient animal models	Increased IGF-1 and somatic-growth-related markers
In-vitro receptor assays	Prolonged GHRH receptor engagement relative to native GHRH

The strongest conclusions supported by the supplied material concern pharmacokinetics and sustained GH/IGF-1 signalling, while broader body-composition and regenerative claims rely more heavily on preclinical evidence.

Potential Stack / Combination Research

The supplied source discusses experimental combinations involving:

CJC-1295 with DAC + Ipamorelin;
CJC-1295 with DAC + BPC-157;
CJC-1295 with DAC + Tesamorelin;
CJC-1295 with DAC + MK-677;
CJC-1295 with DAC + Hexarelin.

The proposed rationale is generally to combine sustained GHRH signalling with other:

GH secretagogues;
ghrelin-receptor agonists;
regenerative compounds;
metabolic research compounds.

However, combining multiple GH-axis compounds can also produce overlapping endocrine effects.

The supplied material does not establish validated human safety, compatibility, efficacy, or dosing for these combinations.

They should therefore be treated as experimental research concepts rather than recommended stacks.

Atlas Longevity CJC-1295 with DAC Pen Dosage / Click Chart

The Atlas Longevity CJC-1295 with DAC pen contains:

5 mg CJC-1295 with DAC

3 mL cartridge volume

300 total clicks

1 click = 0.01 mL

Maximum selectable dial amount = 60 clicks

Pen Specification

Pen Strength	Volume	Concentration	Amount Per Click
5 mg	3 mL	≈1.667 mg/mL	≈0.0167 mg / 16.7 mcg

Concentration Calculation

5 mg ÷ 3 mL = 1.6667 mg/mL

Rounded:

≈1.667 mg/mL

Amount Per Click

5 mg ÷ 300 clicks = 0.016667 mg

Therefore:

1 click ≈0.0167 mg

or:

≈16.7 mcg CJC-1295 with DAC

CJC-1295 with DAC Click Conversion Chart

Clicks	Volume	CJC-1295 with DAC Amount
1	0.01 mL	≈0.0167 mg / 16.7 mcg
5	0.05 mL	≈0.0833 mg
10	0.10 mL	≈0.1667 mg
15	0.15 mL	0.250 mg
20	0.20 mL	≈0.333 mg
30	0.30 mL	0.500 mg
40	0.40 mL	≈0.667 mg
45	0.45 mL	0.750 mg
50	0.50 mL	≈0.833 mg
60	0.60 mL	1.000 mg

Useful Conversions

15 clicks = 0.25 mg
30 clicks = 0.50 mg
45 clicks = 0.75 mg
60 clicks = 1 mg

The maximum selectable amount in one dial operation is:

60 clicks = 0.60 mL = 1 mg CJC-1295 with DAC

This is a mathematical concentration conversion and not a dosing recommendation.

Protocol / Dosage Information

The supplied source describes experimental quantities ranging approximately from:

0.5 mg to 2 mg

Its original pen formulation used:

5 mg in 2 mL

so its click values do not apply to the Atlas Longevity 3 mL / 300-click system.

Using the Atlas formulation:

Source-Referenced Amount	Atlas Pen Mathematical Equivalent
0.25 mg	15 clicks
0.50 mg	30 clicks
0.75 mg	45 clicks
1.00 mg	60 clicks
1.50 mg	90 total clicks
2.00 mg	120 total clicks

Important Pen Limitation

The Atlas pen allows a maximum single dial selection of:

60 clicks

which equals:

1 mg CJC-1295 with DAC

Therefore:

1.5 mg = 90 clicks mathematically;
2 mg = 120 clicks mathematically.

These quantities cannot be selected as one dial amount.

The larger click equivalents are shown only to translate research quantities appearing in the supplied source.

They are not instructions to divide, repeat, or administer multiple injections.

The source also provides weekly, twice-weekly, continuous, combination, and cycle-duration schedules. Those should not be reproduced as self-administration instructions for the Atlas product.

Possible Side Effects

The supplied material describes several effects reported in limited human or preclinical CJC-1295 with DAC research.

These include:

injection-site redness;
injection-site itching or irritation;
flushing;
temporary warmth;
headache;
dizziness;
fluid retention;
tingling in the extremities;
elevated fasting glucose;
reduced insulin sensitivity.

Glucose and Insulin Effects

Growth hormone can oppose some actions of insulin.

Because CJC-1295 with DAC can produce sustained GH elevation, prolonged exposure may influence:

fasting glucose;
insulin sensitivity;
glucose tolerance.

These effects are particularly relevant when studying a long-acting GH-axis compound.

Fluid Retention

Increased GH/IGF-1 signalling may contribute to temporary fluid retention or peripheral symptoms in some research contexts.

Long-Term GH / IGF-1 Exposure

The source states that serious hepatic, cardiovascular, or endocrine adverse effects were not observed in the limited data it references.

However, this should not be interpreted as proof of long-term safety.

Important research uncertainties include:

prolonged IGF-1 elevation;
chronic GH-axis stimulation;
glucose intolerance;
fluid retention;
abnormal tissue-growth signalling;
medication interactions;
combination secretagogue protocols;
long-term cardiovascular effects.

Product Attributes

Attribute	Information
Compound Name	CJC-1295 with DAC
CAS Number listed by source	863288-34-0
Molecular Formula listed by source	C165H269N47O46
Amino Acid Sequence listed by source	YADAIFTQSYRKVLAQLSARKLLQDIMSR
Peptide Length	29 amino acids
Molecular Weight listed by source	Approximately 3647.2 g/mol
PubChem CID listed by source	91971820
Half-Life listed by source	Approximately 6–8 days
Synonyms	CJC-1295 DAC, Drug Affinity Complex CJC-1295, GRF (1–29) analogue with DAC
Compound Type	Long-acting synthetic GHRH analogue with albumin-binding DAC
Research Focus	GH/IGF-1 axis, endocrine signalling, metabolism and body-composition research

Molecular Specification Note

The supplied source gives a 29-amino-acid sequence while also describing a separate DAC modification responsible for albumin binding.

Because the DAC is a chemical modification beyond the plain peptide sequence, the exact finished-product molecular formula and molecular weight should be confirmed against the Atlas Longevity Certificate of Analysis before final publication.

The same applies to exact salt form and analytical identity.

Included in the Box

Each Atlas Longevity product is carefully packed to support secure storage, clean handling, and convenient research use. Inside the package, you’ll find the essential items needed for organized laboratory handling:

1× Ready-to-Use Injection Pen
10× Ultra-Fine Needles (33G, 4 mm)
10× Alcohol Prep Pads
Protective Foam Insert to help keep the pen secure during transport
Quick-Reference Instruction Panel inside the packaging
Tamper-Evident Security Seal for added package protection

Each component is arranged in a clean, protective presentation designed to keep the product secure and easy to access.

Storage

Storage conditions should follow the instructions supplied specifically with the Atlas Longevity CJC-1295 with DAC formulation.

The reference source provides refrigeration and stability specifications for its own finished formulation. Those conditions should not automatically be transferred to an Atlas Longevity formulation without product-specific stability data.

Follow the temperature requirements, light-protection guidance, shelf-life information, and handling instructions shown on the Atlas Longevity product label or accompanying documentation.

Frequently Asked Questions

What is CJC-1295 with DAC?

CJC-1295 with DAC is a long-acting synthetic analogue of GHRH designed to stimulate endogenous growth hormone secretion.

Its DAC modification allows prolonged association with albumin and substantially extends its biological persistence.

What does DAC mean?

DAC stands for:

Drug Affinity Complex

It is a chemical modification designed to increase the peptide’s affinity for circulating albumin and reduce its rate of clearance.

How does CJC-1295 with DAC work?

CJC-1295 with DAC activates GHRH receptors on pituitary somatotroph cells.

This stimulates endogenous growth hormone release, which can subsequently increase circulating IGF-1.

Is CJC-1295 with DAC growth hormone?

No.

CJC-1295 with DAC is not growth hormone.

It is a GHRH analogue that stimulates the pituitary to release endogenous GH.

What is the difference between CJC-1295 with DAC and without DAC?

The main difference is duration of activity.

With DAC: prolonged albumin-associated exposure and source-reported half-life of approximately 6–8 days.

Without DAC: substantially shorter acting.

Their pharmacokinetics and research applications are therefore different.

What is CJC-1295 with DAC researched for?

Research areas include:

GH secretion;
IGF-1;
GHRH receptor signalling;
GH pulse amplitude;
body composition;
lipid metabolism;
tissue-repair signalling;
endocrine physiology.

Has CJC-1295 with DAC been studied in humans?

Yes.

The supplied material describes limited early human pharmacokinetic and endocrine research.

However, the evidence base is much smaller than that for approved GH-axis medications.

Is CJC-1295 with DAC approved?

No.

The supplied material identifies CJC-1295 with DAC as an investigational research compound without regulatory approval for medical use.

Does CJC-1295 with DAC increase GH?

The supplied human pharmacokinetic research reports sustained increases in mean GH following exposure.

Does CJC-1295 with DAC increase IGF-1?

The source also reports prolonged increases in circulating IGF-1 following CJC-1295 with DAC administration.

These effects form a major part of its research profile.

Does CJC-1295 with DAC permanently increase GH?

The source does not establish permanent GH elevation.

Its research focuses on temporary pharmacological stimulation during the compound’s period of biological activity.

What is the half-life of CJC-1295 with DAC?

The supplied material reports approximately:

6–8 days

with some human pharmacokinetic data describing approximately 5.8–8.1 days.

This is source-reported information and may depend on exact formulation and analytical definition.

How much CJC-1295 with DAC is in each Atlas Longevity pen?

Each Atlas Longevity pen contains:

5 mg in 3 mL.

What is the concentration?

The concentration is:

5 mg ÷ 3 mL = approximately 1.667 mg/mL

How many clicks are in the pen?

Each Atlas Longevity pen contains:

300 total clicks / units

with:

1 click = 0.01 mL

How much CJC-1295 with DAC is in one click?

Each click contains approximately:

0.0167 mg

or:

16.7 mcg CJC-1295 with DAC

How many clicks equal 0.25 mg?

15 clicks = 0.25 mg.

How many clicks equal 0.5 mg?

30 clicks = 0.50 mg.

How many clicks equal 1 mg?

60 clicks = 1 mg.

These are concentration calculations rather than dosing recommendations.

How many clicks equal 2 mg?

Mathematically:

2 mg = 120 clicks

This exceeds the Atlas pen’s maximum single dial setting of 60 clicks.

It therefore cannot be selected as one dial amount.

This is a mathematical conversion only and does not provide instructions for administering that quantity.

What is the maximum selectable amount on the CJC-1295 with DAC pen?

The maximum single dial selection is:

60 clicks

which equals:

0.60 mL

and:

1 mg CJC-1295 with DAC

This describes the mechanical limit of the pen rather than a recommended amount.

How long does the CJC-1295 with DAC pen last?

The complete pen contains:

300 clicks and 5 mg total CJC-1295 with DAC.

For cartridge-capacity calculations only:

10 clicks at a time = 30 administrations
15 clicks at a time = 20 administrations
30 clicks at a time = 10 administrations
60 clicks at a time = 5 administrations

These examples describe pen capacity only.

Does the medication disappear when the dial returns to zero?

No.

After administration, the dial returns to zero while unused formulation remains inside the cartridge.

The remaining CJC-1295 with DAC stays in the pen until all 300 units have been used.

Can CJC-1295 with DAC affect blood glucose?

Potentially.

The supplied source reports increased fasting glucose or reduced insulin sensitivity as possible research observations associated with prolonged GH elevation.

Can CJC-1295 with DAC cause water retention?

The source reports temporary water retention among possible adverse effects.

Can CJC-1295 with DAC be combined with Ipamorelin?

The supplied material discusses CJC-1295 with DAC + Ipamorelin as an experimental GH-axis combination.

Validated human combination safety, compatibility, efficacy, and dosing are not established by the supplied material.

Can CJC-1295 with DAC be combined with Tesamorelin?

The source discusses this experimentally, but both compounds stimulate the GHRH/GH axis.

Overlapping stimulation should not automatically be assumed to provide additional benefit or safety.

Is there an established human dosage for the Atlas CJC-1295 with DAC pen?

The supplied source contains experimental quantities, but CJC-1295 with DAC is not an approved therapeutic product and its source click calculations were based on a different formulation.

The Atlas click chart therefore represents concentration mathematics only.

How should the Atlas Longevity CJC-1295 with DAC pen be stored?

Follow the storage instructions supplied specifically with the actual Atlas Longevity formulation.

The competitor product’s refrigeration and stability specifications apply to its own finished formulation and should not automatically be transferred to Atlas without product-specific stability evidence.

CJC-1295 ( NO DAC )